Soleno Therapeutics Inc (SLNO NASDAQ) stock market data APIs
$39.7851
2.36(5.9%)
as of February 5, 2026
Try our APIs with
free plan!
Soleno Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Prev. Close
39.7851
Open
42.1489
High
42.3955
Low
39.5884
52 wk Range
37.95-90.3199
Market Cap
2 126 M
Shares Outstanding
53 710 K
Revenue
98 675 K
EPS
0.47
Beta
-3.182
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Soleno Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Soleno Therapeutics Inc data using free add-ons & libraries
Get Soleno Therapeutics Inc Fundamental Data
Soleno Therapeutics Inc Fundamental data includes:
- Net Revenue: 98 675 K
- EBITDA: -82 259 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Soleno Therapeutics Inc News
New
VYKAT XR Launch Momentum Could Be A Game Changer For Soleno Therapeutics (SLNO)
Soleno Therapeutics recently highlighted that 2025 was a transformational year, pointing to strong preliminary revenue from the launch of its rare-disease drug VYKAT XR and plans to release full finan...
A Look At Soleno Therapeutics (SLNO) Valuation As VYKAT XR Launch Shapes A “Transformational” 2025
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Soleno Therapeutics (SLNO) jumped nearly 9% after managemen...
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome
Ultragenyx Pharmaceutical RARE announced the resubmission of its biologics license application (“BLA”) to the FDA seeking accelerated approval for AAV gene therapy candidate UX111, which is being ...
Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround
Soleno Therapeutics, Inc. (SLNO) has been beaten down lately with too much selling pressure. While the stock has lost 18.3% over the past four weeks, there is light at the end of the tunnel as it is n...
Get Soleno Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
